Pfizer's Lorbrena Achieves 55% Progression-Free Survival at 7 Years in Lung Cancer Study
PFE is trading near its 52-week low of $23.06 (13% above the low).
Summary
Pfizer announced strong 7-year results for its lung cancer drug Lorbrena, with 55% of patients showing progression-free survival in the CROWN trial. The median progression-free survival was not reached, indicating exceptional long-term efficacy. This positive data strengthens Lorbrena's profile in the competitive advanced NSCLC market and supports its potential for broader use, contributing to Pfizer's oncology portfolio.
At the time of this announcement, PFE was trading at $26.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $149B. The 52-week trading range was $23.06 to $28.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.